![Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire](https://mms.businesswire.com/media/20180924005110/en/675037/23/Epizyme-Logo-Trademark.jpg)
Epizyme Announces the U.S. Food and Drug Administration Lifts Partial Clinical Hold on Tazemetostat Clinical Program | Business Wire
![EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/deadb8b4-db2c-4e44-bffc-db9fd3c5a015/gr1.jpg)
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study - The Lancet Oncology
![Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma | Business Wire Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma | Business Wire](https://mms.businesswire.com/media/20200123005858/en/768408/4/480_Epizyme-ES_Disease_Education-Fact_Sheet.jpg)
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma | Business Wire
Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure–Activity Relationships Insights and Evolution Prospects | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer](https://pub.mdpi-res.com/cancers/cancers-15-01569/article_deploy/html/images/cancers-15-01569-g001.png?1677817327)
Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
![Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A](https://ars.els-cdn.com/content/image/1-s2.0-S0006497118712536-gr1.jpg)
Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A
![Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/39a0389e-5255-43d9-8651-1121f88882df/gr2.jpg)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology
![Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/1d999e19-e581-453a-a14a-6322f3d076dc/gr1.jpg)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial - The Lancet Oncology
![The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment - Yuan - 2021 - Cancer Science - Wiley Online Library The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment - Yuan - 2021 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/84af5301-a0b9-4870-98f1-a796851460e5/cas15122-fig-0001-m.jpg)
The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment - Yuan - 2021 - Cancer Science - Wiley Online Library
![Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma](https://larvolclin.s3.us-west-2.amazonaws.com/resize_16173624884942009616066fe3883954.png)
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
OncLive.com on Twitter: "Watch our upcoming live broadcast reviewing a new indication, clinical trial data, and dosing for TAZVERIK TM (tazemetostat): https://t.co/YKnSN20tj9 https://t.co/ZfU6XQc4Gd" / Twitter
![ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer](https://www.urotoday.com/images/com-doc-importer/16-esmo-2021/esmo-2021-586p-safety-of-tazemetostat-taz-in-combination-with-abiraterone-prednisone-a-p-or-enzalutamide-e-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc/image-0.jpg)
ESMO 2021: Safety of Tazemetostat in Combination With Abiraterone/Prednisone or Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
![Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer | Journal of Medicinal Chemistry Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01370/asset/images/large/jm2c01370_0004.jpeg)
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer | Journal of Medicinal Chemistry
![Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors | Clinical Epigenetics | Full Text Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors | Clinical Epigenetics | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13148-021-01045-1/MediaObjects/13148_2021_1045_Fig1_HTML.png)
Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors | Clinical Epigenetics | Full Text
![Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer](https://pub.mdpi-res.com/cancers/cancers-15-01569/article_deploy/html/images/cancers-15-01569-g003.png?1677817321)
Cancers | Free Full-Text | Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
![Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2119213479/2090684048/gr1.jpg)